chestwall XRT

RADIATION2 trials

Conditions

Breast CancerRadiationStage IB Breast CancerStage II Breast Cancer

Unknown Phase

Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery

Active, not recruitingNCT01872975

NSABP Foundation IncStage IB Breast Cancer, Stage II Breast Cancer

Start: 2013-08-31End: 2028-08-31Target: 1636Updated: 2023-12-27

RecurIndex Guided Avoidance of Regional Nodal Irradiation for Node Positive Breast Cancer

RecruitingNCT04069884

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityBreast Cancer, Radiation

Start: 2019-08-20End: 2030-12-31Target: 540Updated: 2025-09-22

New England Journal of Medicine2025-06-0437 citations

Combined analysis of the MF18‐02/MF18‐03 NEOSENTITURK studies: ypN‐positive disease does not necessitate axillary lymph node dissection in patients with breast cancer with a good response to neoadjuvant chemotherapy as long as radiotherapy is provided

Cancer2024-10-306 citations

RecurIndex-Guided postoperative radiotherapy with or without Avoidance of Irradiation of regional Nodes in 1–3 node-positive breast cancer (RIGAIN): a study protocol for a multicentre, open-label, randomised controlled prospective, phase III trial

BMJ Open2024-07-012 citations

Abstract GS02-07: Loco-Regional Irradiation in Patients with Biopsy-proven Axillary Node Involvement at Presentation Who Become Pathologically Node-negative After Neoadjuvant Chemotherapy: Primary Outcomes of NRG Oncology/NSABP B-51/RTOG 1304

Cancer Research2024-05-0260 citations

Protocol for the T-REX-trial: tailored regional external beam radiotherapy in clinically node-negative breast cancer patients with 1-2 sentinel node macrometastases – an open, multicentre, randomised non-inferiority phase 3 trial

BMJ Open2023-09-0117 citations

Protocol for the postoperative radiotherapy in N1 breast cancer patients (PORT-N1) trial, a prospective multicenter, randomized, controlled, non-inferiority trial of patients receiving breast-conserving surgery or mastectomy

BMC Cancer2022-11-169 citations

Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy.

2021-07-0215 citations

Surgical Management of the Axilla in Clinically Node-Positive Breast Cancer Patients Converting to Clinical Node Negativity through Neoadjuvant Chemotherapy: Current Status, Knowledge Gaps, and Rationale for the EUBREAST-03 AXSANA Study.

2021-03-29112 citations

Abstract SP023: State of the art treatment for neoadjuvant/adjuvant triple negative breast cancer

Cancer Research2021-02-15

Multidisciplinary considerations in the treatment of triple‐negative breast cancer

CA A Cancer Journal for Clinicians2020-09-2815 citations

NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to whole breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence-free interval (IBCR-FI) in patients (pts) with pathologically positive axillary (PPAx) nodes who are ypN0 after neoadjuvant chemotherapy (NC).

Journal of Clinical Oncology2019-05-2071 citations

Abstract OT2-04-01: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to whole breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence-free interval (IBCR-FI) in patients (pts) with pathologically positive axillary (PPAx) nodes who are ypN0 after neoadjuvant chemotherapy (NC): NRG Oncology/NSABP B-51/RTOG 1304

Cancer Research2019-02-153 citations

NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence-free interval (IBCR-FI) in patients (pts) with positive axillary (PAx) nodes who are ypN0 after neoadjuvant chemotherapy (NC).

Journal of Clinical Oncology2018-05-205 citations

NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence free interval (IBCRFI) in patients (pts) with positive axillary (PAx) nodes who are ypN0 after neoadjuvant chemotherapy (NC).

Journal of Clinical Oncology2017-05-2014 citations

Postmastectomy Radiation Therapy

Oncology Times2016-12-252 citations

NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence free interval (IBCRFI) in patients (pts) with positive axillary (PAx) nodes who are ypN0 after neoadjuvant chemotherapy (NC).

Journal of Clinical Oncology2016-05-20

NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) will reduce invasive cancer events in patients (pts) with positive axillary (Ax) nodes who are ypN0 after neoadjuvant chemotherapy (NC).

Journal of Clinical Oncology2015-05-202 citations

NSABP B-51/RTOG 1304: Randomized phase III clinical trial evaluating the role of postmastectomy chest wall and regional nodal XRT (CWRNRT) and post-lumpectomy RNRT in patients (pts) with documented positive axillary (Ax) nodes before neoadjuvant chemotherapy (NC) who convert to pathologically negative Ax nodes after NC.

Journal of Clinical Oncology2014-05-2058 citations

chestwall XRT

Sponsors

Conditions

Unknown Phase

Related Papers